
Devyser Diagnostics (Q3 Review) - Exaggerated reaction, strong Q4 ahead

Direct sales and OPEX positively surprised, while the market pushed the share down on lumpy distributor sales not meeting expectations and a lower-than-expected gross margin. We make some downward estimate revisions but still see a c50% gap to be closed in the coming 12 months.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Devyser Diagnostics (Q3 Review) - Exaggerated reaction, strong Q4 ahead